{"id":"oral-naltrexone-o-ntx","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Nausea"},{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Anxiety"},{"rate":"5-10","effect":"Insomnia"},{"rate":"5-10","effect":"Abdominal pain"},{"rate":"5-10","effect":"Joint/muscle pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Naltrexone competitively binds to opioid receptors (mu, delta, and kappa), preventing endogenous opioids and exogenous opioid drugs from activating these receptors. This mechanism is used clinically to reduce cravings and block the rewarding effects of opioids in opioid use disorder, and at lower doses to modulate immune and pain pathways in other conditions.","oneSentence":"Oral naltrexone is an opioid receptor antagonist that blocks opioid signaling in the central and peripheral nervous system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:39:01.011Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid use disorder (maintenance treatment)"},{"name":"Alcohol use disorder"}]},"trialDetails":[{"nctId":"NCT01893827","phase":"PHASE4","title":"Extended-Release vs. Oral Naltrexone Alcohol Treatment in Primary Care","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2014-06","conditions":"Alcohol Dependence","enrollment":237}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Revia"],"phase":"marketed","status":"active","brandName":"Oral Naltrexone (O-NTX)","genericName":"Oral Naltrexone (O-NTX)","companyName":"NYU Langone Health","companyId":"nyu-langone-health","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oral naltrexone is an opioid antagonist that blocks opioid receptors in the central and peripheral nervous system. Used for Opioid use disorder, Alcohol use disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}